Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Cyclopharm Limited ( (AU:CYC) ) has issued an announcement.
Cyclopharm Limited has signed an agreement with Stanford Medicine Children’s Health for the implementation of its Technegas lung imaging technology at Lucile Packard Children’s Hospital Stanford, the first dedicated children’s hospital in the United States to adopt the product. The installation represents a key milestone in Cyclopharm’s early U.S. commercial rollout, underscoring Technegas’ appeal in paediatric care due to its low radiation dose, established safety profile, and suitability for high-quality functional lung imaging, and supports the company’s broader strategy to expand its presence across leading U.S. academic and clinical centres.
The most recent analyst rating on (AU:CYC) stock is a Hold with a A$0.97 price target. To see the full list of analyst forecasts on Cyclopharm Limited stock, see the AU:CYC Stock Forecast page.
More about Cyclopharm Limited
Cyclopharm Limited is an ASX-listed radiopharmaceutical company that services the global medical community, focusing on nuclear medicine imaging solutions. Its core product, Technegas, is an ultra-fine radioactive carbon dispersion used for functional lung ventilation imaging, historically in the diagnosis of pulmonary embolism and increasingly in conditions such as COPD, asthma, pulmonary hypertension, and in planning and assessing lung cancer surgeries and lung volume reduction procedures.
Average Trading Volume: 72,934
Technical Sentiment Signal: Sell
Current Market Cap: A$104.5M
Find detailed analytics on CYC stock on TipRanks’ Stock Analysis page.